MedTrace Logo

TD-1211 IV/Oral Mass Balance Study

NCT01702194 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-22

No results posted yet for this study

Summary

The purpose of this study is to determine TD-1211 is processed by the body.

Conditions

  • OIC

Interventions

DRUG

TD-1211 IV [C14]

DRUG

TD-1211 PO [C14]

Sponsors & Collaborators

  • Glycyx Therapeutics

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Theravance Biopharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-02-28
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702194 on ClinicalTrials.gov